Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
URGN Stock Forecast 2026-2027
$39.80
Current Price
$1.91B
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to URGN Price Targets
+13.1%
To High Target of $45.00
+0.5%
To Median Target of $40.00
-54.8%
To Low Target of $18.00
URGN Price Momentum
-1.1%
1 Week Change
+24.6%
1 Month Change
+177.5%
1 Year Change
+69.9%
Year-to-Date Change
-2.6%
From 52W High of $40.87
+188.6%
From 52W Low of $13.79
📊 TOP ANALYST CALLS
Did URGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if UroGen is one of their latest high-conviction picks.
Latest URGN Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, URGN has a bullish consensus with a median price target of $40.00 (ranging from $18.00 to $45.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $39.80, the median forecast implies a 0.5% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 13.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
URGN Analyst Ratings
6
Buy
1
Hold
0
Sell
URGN Price Target Range
Low
$18.00
Average
$40.00
High
$45.00
Current: $39.80
Latest URGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for URGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 3, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $45.00 |
| May 18, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 11, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 7, 2026 | Oppenheimer | Outperform | Maintains | $N/A | |
| Mar 31, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 2, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 23, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 5, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Oct 27, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 27, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Oct 3, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 19, 2025 | Piper Sandler | Overweight | Initiates | $N/A | |
| Aug 11, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 7, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 5, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jul 8, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 7, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jun 16, 2025 | HC Wainwright & Co. | Buy | Upgrade | $N/A | |
| Jun 13, 2025 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| Jun 13, 2025 | Guggenheim | Buy | Maintains | $N/A |
Urogen Pharma Ltd. (URGN) Competitors
The following stocks are similar to UroGen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Urogen Pharma Ltd. (URGN) Financial Data
Urogen Pharma Ltd. has a market capitalization of $1.91B with a P/E ratio of -12.6x. The company generates $140.49M in trailing twelve-month revenue with a -94.8% profit margin.
Revenue growth is +151.6% quarter-over-quarter, while maintaining an operating margin of -39.8% and return on equity of +145.5%.
Valuation Metrics
Market Cap
$1.91B
Enterprise Value
$1.98B
P/E Ratio
-12.6x
PEG Ratio
0.3x
Price/Sales
13.5x
Growth & Margins
Revenue Growth (YoY)
+151.6%
Gross Margin
+91.9%
Operating Margin
-39.8%
Net Margin
-94.8%
EPS Growth
+151.6%
Financial Health
Cash/Price Ratio
+7.2%
Current Ratio
4.7x
Debt/Equity
-1.6x
ROE
+145.5%
ROA
-27.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Urogen Pharma Ltd. (URGN) Business Model
About Urogen Pharma Ltd.
What They Do
Develops innovative treatments for urological cancers.
Business Model
UroGen Pharma Ltd. operates in the biopharmaceutical sector, focusing on developing therapies for urological cancers using its proprietary RTGel technology. The company generates revenue through the sale of its FDA-approved products, such as Jelmyto and Zusduri, and continues to advance its pipeline of product candidates, which may provide future income through new therapies.
Additional Information
The company's approach enhances drug delivery directly to targeted tissues, leading to localized treatment with reduced systemic side effects. UroGen Pharma is positioned as a key player in uro-oncology, providing non-surgical alternatives and improving patient access to advanced treatments for bladder and upper tract cancers.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
298
CEO
Ms. Elizabeth A. Barrett
Country
United States
IPO Year
2017
Website
www.urogen.comUrogen Pharma Ltd. (URGN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Jul 07, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
UroGen Pharma Ltd. announced news from Princeton, N.J. on July 15, 2026. Further details were not provided in the excerpt.
Why It Matters
UroGen Pharma's news could signal developments in drug approvals or financial performance, impacting stock prices and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
UroGen Pharma's CMO sold 10,000 shares at $40 each, totaling $400,000, which is 8% of their direct equity holdings, according to a Form 4 filing.
Why It Matters
Insider selling can signal lack of confidence in the company's future. A significant sale by the CMO may raise concerns about UroGen Pharma's prospects among investors.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
UroGen Pharma received FDA clearance to start a Phase 1 study for UGN-501, an oncolytic virus targeting tumors. Patient enrollment is set to begin in Q4 2026.
Why It Matters
FDA clearance for UGN-501's Phase 1 study signals potential advancements in cancer treatment, which could enhance UroGen Pharma's market position and attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Urogen Pharma (URGN) is being evaluated for its potential as a top stock choice for momentum investors.
Why It Matters
Urogen Pharma's potential as a momentum stock indicates possible growth opportunities, attracting investors seeking high returns amid market trends.
Source: Zacks Investment Research
Market Sentiment:
Positive
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
15 days ago
Quick Summary
On June 22, 2026, Mark Schoenberg sold 10,000 shares for ~$350,000 at ~$35.01 per share, reducing his holdings by 7.15% from 139,763 to 129,763 shares.
Why It Matters
Mark Schoenberg's sale of 10,000 shares may signal a lack of confidence or liquidity needs, potentially impacting investor sentiment and stock price movement.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Mark Schoenberg sold 5,222 shares on June 8, 2026, for about $143,000 at $27.30 per share, reducing his holdings by 3.60% to 139,763 shares.
Why It Matters
Mark Schoenberg's sale of 3.60% of his holdings may signal a lack of confidence in the stock's future performance, potentially influencing investor sentiment and share price.
Source: The Motley Fool
Market Sentiment:
Neutral
Frequently Asked Questions About URGN Stock
What is Urogen Pharma Ltd.'s (URGN) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Urogen Pharma Ltd. (URGN) has a median price target of $40.00. The highest price target is $45.00 and the lowest is $18.00.
Is URGN stock a good investment in 2027?
According to current analyst ratings, URGN has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $39.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for URGN stock?
Wall Street analysts predict URGN stock could reach $40.00 in the next 12 months. This represents a 0.5% increase from the current price of $39.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Urogen Pharma Ltd.'s business model?
UroGen Pharma Ltd. operates in the biopharmaceutical sector, focusing on developing therapies for urological cancers using its proprietary RTGel technology. The company generates revenue through the sale of its FDA-approved products, such as Jelmyto and Zusduri, and continues to advance its pipeline of product candidates, which may provide future income through new therapies.
What is the highest forecasted price for URGN Urogen Pharma Ltd.?
The highest price target for URGN is $45.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 13.1% increase from the current price of $39.80.
What is the lowest forecasted price for URGN Urogen Pharma Ltd.?
The lowest price target for URGN is $18.00 from at , which represents a -54.8% decrease from the current price of $39.80.
What is the overall URGN consensus from analysts for Urogen Pharma Ltd.?
The overall analyst consensus for URGN is bullish. Out of 3 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $40.00.
How accurate are URGN stock price projections?
Stock price projections, including those for Urogen Pharma Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 4:59 PM UTC